Can a tiny balloon in the womb help babies breathe?
NCT ID NCT07767825
First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time
Summary
This pilot trial tests a procedure called FETO for fetuses with severe congenital diaphragmatic hernia (CDH), a condition where the diaphragm has a hole and the lungs don't develop fully. In FETO, a balloon is temporarily placed in the fetal windpipe to encourage lung growth, then removed before birth. The study enrolls 10 pregnant individuals and aims to see if the balloon can be safely placed and removed. If it works, this could offer a new way to improve outcomes for these babies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Fetoscopic endoluminal tracheal occlusion (FETO) using a detachable balloon
- What this could lead to
- If successful, this procedure could improve lung growth and survival for babies with severe CDH, offering a new treatment option before birth.
- What could go wrong
- This is a small pilot study focused on feasibility, not proof of benefit. The procedure carries risks to both mother and fetus, and results may not generalize.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 10 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Provision of a signed and dated informed consent form 2. Pregnant individuals age 18 years and older 3. Singleton pregnancy 4. A normal karyotype with confirmation by culture results, CMA with non-pathologic variants, whole exome or genome sequencing (WES or WGS). 5. Isolated left CDH with severe pulmonary hypoplasia with o/e LHR less than 25% with liver up (measured at 18 weeks 0 days to 29 weeks 5 days of gestation) 6. Isolated right CDH with severe pulmonary hypoplasia with o/e LHR equal or less than 30% with liver up (measured at 18 weeks 0 days to 29 weeks 5 days of gestation) 7. Gestational age at FETO procedure 27 weeks 0 days to 29 weeks 6 days as determined by clinical information (LMP) and evaluation of first ultrasound 8. Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study 9. Willing to reside within a 30-minute distance of the NYULH in the time period between the FETO placement procedure and the balloon retrieval procedure, and ability to maintain follow-up appointments 10. The subject has a support person (e.g., spouse, partner, friend, parent) who is available to stay with her for the duration of the pregnancy near NYULH. 11. Willing to comply with restrictions of daily living, including inability to exercise, have intercourse, or return to work 12. Meets psychosocial criteria Exclusion Criteria: 1. Natural rubber latex allergy 2. Additional fetal anomaly and chromosomal abnormalities, associated anomalies recognized to alter survival prognosis (i.e., congenital heart disease) or presence of an underlying genetic syndrome (i.e., Fryns) by ultrasound, MRI or echocardiogram at the fetal treatment center. 3. Signs of preterm labor, cervix shortened to ≤20 mm at enrollment or at 24 hours prior to FETO balloon insertion procedure) or a uterine anomaly strongly predisposing to preterm labor. 4. Maternal contraindication to fetoscopic surgery or severe maternal medical condition in pregnancy 5. History of incompetent cervix with or without cerclage 6. Placental abnormalities (previa, abruption, accreta, chorioangioma) known at time of enrollment 7. Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy 8. Maternal HIV, Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment 9. Uterine anomaly such as large or multiple fibroids or mullerian duct abnormality 10. There is no safe or technically feasible fetoscopic approach to balloon placement 11. Participation in another intervention study that influences maternal and fetal morbidity and mortality 12. Any other condition which, in the opinion of the investigator, would compromise safety, feasibility or impede compliance. 13. Bilateral CDH, isolated left sided CDH with o/e LHR \>/= 25% and isolated right sided CDH \>30% 14. No intrathoracic liver herniation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Severe congenital diaphragmatic hernia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
NYU Langone Health
New York, New York, 10016, United States